Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, announces that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics (“Bako”), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire certain assets of Bako Diagnostics and will acquire StrataDx for a total combined purchase price of approximately $55.5 million, subject to adjustments, to be paid from cash on hand.
Read the full article: Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx //
Source: https://www.businesswire.com/news/home/20251222736495/en/Fulgent-Genetics-Agrees-to-Acquire-Bako-Diagnostics-and-StrataDx